



Corrigendum

Corrigendum to 'A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer' *Eur J Cancer* 2001, **37**, S264–S265. R. Pirker, J. Vansteenkiste, J. Gateley, P. Yates, A. Colowick, J. Musil

R. Pirker

Medicine I, University of Vienna, Vienna, Austria

A typographical error occurred within the results section of the above mentioned abstract. The correct sentence appears below.

NESP pts received fewer standard units (mean [SD]) of RBC than placebo patients during wks 5–12: NESP 0.67 (1.7), placebo 1.92 (3.27) and during the treatment phase: NESP 1.14 (2.38), placebo 2.64 (4.32).

E-mail address: robert-pirker@akh.wien (R. Pirker).